Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kathryn Edwards

Pediatric Infectious Diseases Nashville, TN Medical Doctor

NPI 1104918523 CMS profile 651167

3601 Tvc, Nashville, TN 37232

Open in the dashboard

General payments

$332,289

200 records reported · program years 2019–2025

Research payments

$36,957

Paid to them · 30 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,170 paid to institutions, not to them · program year 2021

Through program year 2025, Kathryn Edwards of Nashville, TN is reported in the CMS Open Payments database as having received $332,289 across 200 general payments and $36,957 in research payments paid to them. Separately, studies naming them as principal investigator received $1,170 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Pediatric Infectious Diseases profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

13 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $68,979 33
2025 Research $1,215 1
2024 General $64,717 44
2024 Research $7,750 7
2023 General $68,970 50
2023 Research $6,900 5
2022 General $55,975 30
2022 Research $5,070 5
2021 General $26,788 13
2021 Research $8,925 9
2020 General $39,931 14
2019 General $6,930 16
2019 Research $7,097 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kathryn Edwards
  • Pediatric Infectious Diseases median
  • Middle half of Pediatric Infectious Diseases
  • National median

In program year 2025, general payments to Kathryn Edwards were reported at $68,979. Among 311 Pediatric Infectious Diseases profiles paid that year, the median was $126 and the middle half received between $41 and $2,094.

Show as a table
Year Kathryn Edwards Pediatric Infectious Diseases median Middle half National median
2019 $6,930 $175 $34–$2,175 $163
2020 $39,931 $521 $34–$6,009 $114
2021 $26,788 $1,077 $39–$4,557 $132
2022 $55,975 $232 $53–$6,196 $149
2023 $68,970 $140 $52–$4,662 $160
2024 $64,717 $198 $52–$3,860 $164
2025 $68,979 $126 $41–$2,094 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $106,971 39 payments
  2. Merck Sharp & Dohme Corporation $55,914 74 payments
  3. Moderna TX, Inc. $50,731 32 payments
  4. AstraZeneca Pharmaceuticals LP $36,291 15 payments
  5. GlaxoSmithKline, LLC. $22,628 8 payments
  6. Dynavax Technologies Corporation $13,484 7 payments
  7. Sanofi Pasteur Inc. $12,506 9 payments
  8. Eli Lilly and Company $6,525 1 payment
  9. Seqirus USA Inc $6,000 4 payments
  10. Janssen Research & Development, LLC $5,980 1 payment
  11. Other $15,260 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $293,220 156 payments
  2. Travel and Lodging $25,932 23 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $9,903 3 payments
  4. Honoraria $2,000 1 payment
  5. Food and Beverage $1,234 17 payments
Products named General payments · program years 2019–2025
  1. Heplisav-B $13,484 7 payments
  2. FLUCELVAX QUADRIVALENT (MULTI-DOSE VIAL) $6,000 4 payments
  3. ENFLONSIA $3,488 9 payments
  4. FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE $2,408 2 payments
  5. FLUMIST QUADRIVALENT $1,820 1 payment
  6. Non-Covered Product $1,305 1 payment
  7. NOVAVAX COVID-19 VACCINE, ADJUVANTED Vaccine $1,300 2 payments
  8. NOVAVAX COVID-19 VACCINE, ADJUVANTED Vaccine $1,200 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Seqirus USA Inc $20,775 18 payments
  2. Moderna TX, Inc. $7,870 8 payments
  3. Sanofi Pasteur Inc. $7,097 3 payments
  4. Bavarian Nordic A/S $1,215 1 payment

Records

230 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Infectious Diseases in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record